Catalyst Pharmaceuticals Shares Outstanding 2006-2018 | CPRX

Catalyst Pharmaceuticals shares outstanding from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Catalyst Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2017 86
2016 83
2015 81
2014 64
2013 45
2012 30
2011 22
2010 19
2009 15
2008 13
2007 13
2006 8
2005 6
Catalyst Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
Q3 2018 103
Q2 2018 103
Q1 2018 103
Q4 2017 86
Q3 2017 85
Q2 2017 84
Q1 2017 83
Q4 2016 83
Q3 2016 83
Q2 2016 83
Q1 2016 83
Q4 2015 81
Q3 2015 82
Q2 2015 82
Q1 2015 76
Q4 2014 64
Q3 2014 67
Q2 2014 66
Q1 2014 54
Q4 2013 45
Q3 2013 45
Q2 2013 41
Q1 2013 41
Q4 2012 30
Q3 2012 32
Q2 2012 27
Q1 2012 25
Q4 2011 22
Q3 2011 22
Q2 2011 22
Q1 2011 20
Q4 2010 19
Q3 2010 19
Q2 2010 18
Q1 2010 18
Q4 2009 15
Q3 2009 14
Q2 2009 14
Q1 2009 14
Q4 2008 13
Q3 2008 13
Q2 2008 13
Q1 2008 13
Q4 2007 13
Q3 2007 13
Q2 2007 13
Q1 2007 13
Q4 2006 8
Q3 2006 7
Q2 2006 7
Q1 2006 7
Q3 2005 7
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.284B $0.000B
CATALYST PHARMACEUTICAL PARTNERS, INC. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the US relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending worldwide. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted `Fast Track` status by the U.S. Food & Drug Administration for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $45.191B 30.06
Takeda Pharmaceutical (TAK) Japan $31.497B 11.65
Grifols (GRFS) Spain $13.400B 16.24
Ionis Pharmaceuticals (IONS) United States $8.030B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $7.648B 10.98
Tilray (TLRY) United States $7.556B 0.00
Nektar Therapeutics (NKTR) United States $7.448B 10.68
Neurocrine Biosciences (NBIX) United States $7.208B 466.82
Sage Therapeutics (SAGE) United States $6.954B 0.00
Catalent (CTLT) United States $6.232B 26.09
United Therapeutics (UTHR) United States $5.138B 8.40
FibroGen (FGEN) United States $4.882B 0.00
Taro Pharmaceutical Industries (TARO) Israel $4.037B 12.99
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $4.022B 21.38
USANA Health Sciences (USNA) United States $2.385B 19.47
Endo (ENDP) Ireland $2.369B 3.63
Heron Therapeutics (HRTX) United States $2.211B 0.00
Ironwood Pharmaceuticals (IRWD) United States $2.203B 0.00
Zogenix (ZGNX) United States $1.996B 0.00
Portola Pharmaceuticals (PTLA) United States $1.990B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.953B 24.32
Xencor (XNCR) United States $1.896B 0.00
Madrigal Pharmaceuticals (MDGL) United States $1.893B 0.00
Aerie Pharmaceuticals (AERI) United States $1.800B 0.00
PTC Therapeutics (PTCT) United States $1.785B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $1.705B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.655B 223.61
Theravance Biopharma (TBPH) Cayman Islands $1.496B 0.00
Corcept Therapeutics (CORT) United States $1.307B 19.19
TherapeuticsMD (TXMD) United States $1.299B 0.00
Spectrum Pharmaceuticals (SPPI) United States $1.242B 0.00
Esperion Therapeutics (ESPR) United States $1.176B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.985B 0.00
Tricida (TCDA) United States $0.961B 0.00
Radius Health (RDUS) United States $0.860B 0.00
ImmunoGen (IMGN) United States $0.833B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.587B 0.00
Karyopharm Therapeutics (KPTI) United States $0.566B 0.00
ChemoCentryx (CCXI) United States $0.560B 44.36
Siga Technologies (SIGA) United States $0.560B 0.00
Flexion Therapeutics (FLXN) United States $0.547B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.540B 0.00
GlycoMimetics (GLYC) United States $0.511B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.510B 30.09
Collegium Pharmaceutical (COLL) United States $0.498B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.479B 0.00
Forty Seven (FTSV) United States $0.476B 0.00
Odonate Therapeutics (ODT) United States $0.447B 0.00
Aptorum Group (APM) China $0.428B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.392B 0.00
Translate Bio (TBIO) United States $0.386B 0.00
Lannett Co Inc (LCI) United States $0.385B 3.58
Akebia Therapeutics (AKBA) United States $0.374B 0.00
ArQule (ARQL) United States $0.361B 0.00
HARPOON THERAPT (HARP) United States $0.350B 0.00
CASI Pharmaceuticals (CASI) United States $0.345B 0.00
KalVista Pharmaceuticals (KALV) United States $0.345B 0.00
Concert Pharmaceuticals (CNCE) United States $0.342B 0.00
Tyme Technologies (TYME) United States $0.330B 0.00
Dermira (DERM) United States $0.314B 0.00
Minerva Neurosciences (NERV) United States $0.306B 0.00
OptiNose (OPTN) United States $0.297B 0.00
Majesco Entertainment (PTE) United States $0.295B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.289B 10.76
Verrica Pharmaceuticals (VRCA) United States $0.286B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.275B 0.00
Aclaris Therapeutics (ACRS) United States $0.268B 0.00
Galectin Therapeutics (GALT) United States $0.246B 0.00
Mast Therapeutics (SVRA) United States $0.236B 0.00
Opexa Therapeutics (ACER) United States $0.231B 0.00
IMV INC (IMV) Canada $0.217B 0.00
Dova Pharmaceuticals (DOVA) United States $0.216B 0.00
Aratana Therapeutics (PETX) United States $0.213B 0.00
Affimed (AFMD) Germany $0.212B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.211B 0.00
Calithera Biosciences (CALA) United States $0.210B 0.00
Rafael Holdings (RFL) United States $0.207B 0.00
Xeris Pharmaceuticals (XERS) United States $0.206B 0.00
Aldeyra Therapeutics (ALDX) United States $0.203B 0.00
MEI Pharma (MEIP) United States $0.198B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.197B 0.00
ElectroCore (ECOR) United States $0.196B 0.00
Taiwan Liposome, Unsponsored ADR (TLC) Taiwan $0.189B 0.00
Recro Pharma (REPH) United States $0.188B 0.00
Molecular Templates (MTEM) United States $0.175B 0.00
Redhill Biopharma (RDHL) Israel $0.173B 0.00
Zafgen (ZFGN) United States $0.173B 0.00
Ardelyx (ARDX) United States $0.163B 0.00
AgeX Therapeutics (AGE) United States $0.162B 0.00
Nature's Sunshine Products (NATR) United States $0.159B 0.00
Aquestive Therapeutics (AQST) United States $0.157B 0.00
Ocular Therapeutix (OCUL) United States $0.154B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.153B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.150B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.148B 0.00
Adherex Technologies (FENC) United States $0.143B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.139B 0.00
Neon Therapeutics (NTGN) United States $0.136B 0.00
Jounce Therapeutics (JNCE) United States $0.133B 0.00
MediWound (MDWD) Israel $0.129B 0.00
Cardiome Pharma (CORV) Canada $0.125B 0.00
ProNAi Therapeutics (SRRA) Canada $0.120B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.119B 0.00
DURECT (DRRX) United States $0.119B 0.00
China SXT Pharmaceuticals (SXTC) China $0.116B 0.00
Matinas Biopharma Holdings (MTNB) United States $0.115B 0.00
Oasmia Pharmaceutical AB (OASM) Sweden $0.101B 0.00
Champions Oncology (CSBR) United States $0.098B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.086B 0.00
Natural Alternatives (NAII) United States $0.083B 8.13
Nivalis Therapeutics (ALPN) United States $0.083B 0.00
Iterum Therapeutics (ITRM) Ireland $0.081B 0.00
Infinity Pharmaceuticals (INFI) United States $0.078B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.076B 0.00
Actinium Pharmaceuticals (ATNM) United States $0.075B 0.00
Melinta Therapeutics (MLNT) United States $0.075B 0.00
Synergy Pharmaceuticals (SGYP) United States $0.074B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.074B 0.00
Ampio Pharmaceuticals (AMPE) United States $0.071B 0.00
Neos Therapeutics (NEOS) United States $0.071B 0.00
Immune Design (IMDZ) United States $0.068B 0.00
SCYNEXIS (SCYX) United States $0.068B 0.00
Forward Pharma (FWP) Denmark $0.063B 0.00
Otonomy (OTIC) United States $0.061B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.061B 0.00
Avenue Therapeutics (ATXI) United States $0.061B 0.00
Zomedica Pharmaceuticals (ZOM) United States $0.061B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.057B 0.00
KemPharm (KMPH) United States $0.056B 0.00
CTI BioPharma (CTIC) United States $0.054B 0.00
Mannatechorporated (MTEX) United States $0.045B 0.00
Genocea Biosciences (GNCA) United States $0.043B 0.00
BioLineRx (BLRX) Israel $0.042B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.042B 0.00
Achaogen (AKAO) United States $0.041B 0.00
Tokai Pharmaceuticals (NVUS) United States $0.041B 0.00
ContraFect (CFRX) United States $0.037B 0.00
Capnia (SLNO) United States $0.036B 0.00
Lipocine (LPCN) United States $0.036B 0.00
Heat Biologics (HTBX) United States $0.034B 0.00
ProPhase Labs (PRPH) United States $0.034B 0.00
NOVAN INC (NOVN) United States $0.030B 0.00
NanoViricides (NNVC) United States $0.029B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.028B 0.00
PharmAthene (ALT) United States $0.025B 0.00
IsoRay (ISR) United States $0.024B 0.00
ESSA Pharma (EPIX) Canada $0.024B 0.00
Can-Fite Biopharma (CANF) Israel $0.023B 0.00
Biomerica (BMRA) United States $0.022B 0.00
Cyanotech (CYAN) United States $0.020B 0.00
Onconova Therapeutics (ONTX) United States $0.020B 0.00
Citius Pharmaceuticals (CTXR) United States $0.020B 0.00
CollPlant Holdings Sponsored ADR (CLGN) Israel $0.019B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.019B 0.00
Xenetic Biosciences (XBIO) United States $0.019B 0.00
Pain Therapeutics (PTIE) United States $0.018B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.018B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.018B 0.00
Trillium Therapeutics (TRIL) Canada $0.018B 0.00
HANCOCK JAFFE (HJLI) United States $0.018B 0.00
Jaguar Animal Health (JAGX) United States $0.015B 0.00
VAXART, INC (VXRT) United States $0.014B 0.00
Auris Medical Holding AG (EARS) Switzerland $0.014B 0.00
PRECISION THERAPEUTICS INC (AIPT) United States $0.013B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.012B 0.00
Shineco (TYHT) China $0.011B 1.25
OncoGenex Pharmaceuticals (ACHV) United States $0.011B 0.00
DelMar Pharmaceuticals (DMPI) Canada $0.009B 0.00
Regulus Therapeutics (RGLS) United States $0.009B 0.00
Intellipharmaceutics (IPCI) Canada $0.007B 0.00
RXi Pharmaceuticals (PHIO) United States $0.007B 0.00
Ohr Pharmaceuticals (OHRP) United States $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
Bio Blast Pharma (ORPN) Israel $0.005B 0.00
Midatech Pharma (MTP) United Kingdom $0.004B 0.00
Ritter Pharmaceuticals (RTTR) United States $0.004B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.003B 0.00
Bio-Path Holdings (BPTH) United States $0.002B 0.00
Advanced Accelerator Applications (AAAP) France $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00